| 000 | 01373 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250515175909.0 | ||
| 264 | 0 | _c20091113 | |
| 008 | 200911s 0 0 eng d | ||
| 022 | _a1873-5169 | ||
| 024 | 7 |
_a10.1016/j.peptides.2009.06.026 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFaludi, Peter | |
| 245 | 0 | 0 |
_aThe effect of exenatide re-exposure on safety and efficacy. _h[electronic resource] |
| 260 |
_bPeptides _cSep 2009 |
||
| 300 |
_a1771-4 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies _xblood |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xblood |
| 650 | 0 | 4 |
_aDrug Hypersensitivity _xepidemiology |
| 650 | 0 | 4 | _aExenatide |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGlycated Hemoglobin _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPeptides _xadverse effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVenoms _xadverse effects |
| 700 | 1 | _aBrodows, Robert | |
| 700 | 1 | _aBurger, Jude | |
| 700 | 1 | _aIvanyi, Tibor | |
| 700 | 1 | _aBraun, Daniel K | |
| 773 | 0 |
_tPeptides _gvol. 30 _gno. 9 _gp. 1771-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.peptides.2009.06.026 _zAvailable from publisher's website |
| 999 |
_c18992169 _d18992169 |
||